Primary therapy in breast cancer: what have we learned from landmark trials?

Author： Bozza Claudia   Osa Etin-Osa   Puglisi Fabio  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.9, Iss.6, 2013-11, pp. : 583-593

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 39-46

Karger

Access to resources Recommend Favorite

Histone deacetylase inhibitors in cancer: What have we learned?

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : 1164-1167

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapeutic vaccines for prostate cancer: what have we learned?

By Gulley James L  

Therapy, Vol. 5, Iss. 1, 2008-01 ,pp. : 3-5

Future Medicine

Access to resources Recommend Favorite

What We Have Learned From a Decade of ED Crowding Research

By  

ACADEMIC EMERGENCY MEDICINE, Vol. 22, Iss. 8, 2015-08 ,pp. : 985-987

John Wiley & Sons Inc

Access to resources Recommend Favorite

Contralateral biopsy in the management of testicular cancer: what we have learned and what we need to improve

By  

ANDROLOGY, Vol. 3, Iss. 1, 2015-01 ,pp. : 99-101

John Wiley & Sons Inc

Access to resources Recommend Favorite